Eversept Partners’s AnaptysBio ANAB Stock Holding History

Eversept Partners’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.72M	Buy	69,983 +42,894	+158%	+$2.6M	0.25%	69
2026 Q1	$1.5M	Sell	27,089 -93,838	-78%	-$5.05M	0.08%	96
2025 Q4	$5.86M	Buy	+120,927	New	+$4.71M	0.3%	66
2022 Q3	–	Sell	-182,717	Closed	-$3.71M	–	72
2022 Q2	$3.71M	Buy	182,717 +68,552	+60%	+$1.52M	0.26%	52
2022 Q1	$2.82M	Sell	114,165 -68,447	-37%	-$2.07M	0.22%	55
2021 Q4	$6.35M	Buy	182,612 +104,558	+134%	+$3.32M	0.41%	59
2021 Q3	$2.12M	Buy	+78,054	New	+$1.98M	0.15%	75
2021 Q1	–	Sell	-88,334	Closed	-$1.9M	–	87
2020 Q4	$1.9M	Buy	+88,334	New	+$2.15M	0.22%	43
2018 Q4	–	Sell	-22,524	Closed	-$2.25M	–	55
2018 Q3	$2.25M	Sell	22,524 -10,110	-31%	-$839K	0.99%	20
2018 Q2	$2.32M	Buy	+32,634	New	+$2.74M	1.06%	22

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Eversept Partners's ANAB Position: Q2 2026 in Review

Eversept Partners increased its AnaptysBio (ANAB) stake by 158% in Q2 2026, buying an estimated $2.6M and bringing the position to 69,983 shares worth $4.72M. The position accounts for 0.25% of the portfolio, ranked #69.

Eversept Partners first reported a position in ANAB in Q2 2018 and has held it in 10 quarters since. The position peaked at $6.35M in Q4 2021. 214 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Eversept Partners held 69,983 shares of AnaptysBio worth $4.72M as of Q2 2026.
Eversept Partners bought 42,894 AnaptysBio shares in Q2 2026, an estimated $2.6M.
AnaptysBio made up 0.25% of Eversept Partners's portfolio in Q2 2026, its #69 holding.
Eversept Partners first reported a position in AnaptysBio in Q2 2018 and has held it in 10 quarters since.
Eversept Partners's AnaptysBio position peaked at $6.35M in Q4 2021.
214 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.